SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz among traders who are attracted to its active developer engagement and the community's push to build organic momentum, despite the project's early stage and lack of an official chart. Investors are actively discussing the potential for a significant breakout, emphasizing the need for sustained volume and broader social media promotion to move the token toward mainstream visibility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Guy is gaining traction as investors rally behind its status as an iconic, original meme, with the community actively promoting its restored meme-generation tools and historical roots on the Solana network. Supporters are focused on long-term conviction and 'bagwork,' positioning the token as a primary contender in the current meme coin cycle by emphasizing its deep cultural heritage and utility for content creation.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy (MULN CRYPTO) is currently trending as members debate its viability, with many in the community labeling it a pump-and-dump scheme or comparing it to the Mullen Automotive stock decline. While some users attempt to rally interest through community-led narratives and crypto-market speculation, others are actively warning investors to exit to avoid potential financial losses.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community remains deeply divided, with some investors accumulating tokens in anticipation of regulatory clarity and institutional adoption, while others express frustration over long-term price stagnation and perceived lack of progress. Debates are currently fueled by speculation surrounding the Clarity Act and the expansion of Ripple's payment infrastructure, leading to a polarized environment between optimistic long-term holders and disillusioned skeptics.

iShares Inc. - iShares MSCI Mexico ETF

iShares MSCI Mexico ETF

Investors are actively debating the long-term viability of Mexico as a manufacturing hub, with some noting its strategic importance in nearshoring supply chains while others warn of socio-economic decay and political risks. The community is focused on the impact of trade tariffs and US-Mexico relations on the performance of $EWW.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors monitor its development as a rare earth metals processor amid increasing urgency for U.S.-aligned supply chains. The community is actively debating the stock's long-term potential in the defense sector, with heavy discussions focused on the company's advisory board appointments, defense-related contracts, and the risks versus rewards associated with future production timelines.

ETF Series Solutions - ESS U.S.Global Jets ETF

US Global Jets ETF

Airline stocks are facing renewed volatility as the sector grapples with potential operational disruptions, fuel cost pressures, and broader economic uncertainty. The community is actively debating the sustainability of travel demand and debating whether the recent price action offers a contrarian value opportunity or a warning of deeper industry headwinds.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to clinical progress with its ITK inhibitor, soquelitinib, which has generated buzz for its potential to deliver durable, disease-modifying outcomes in atopic dermatitis and oncology. Community sentiment remains highly polarized, with intense debate between bulls anticipating a strategic buyout or short squeeze and skeptics emphasizing the inherent risks of a clinical-stage biotech and the potential for share dilution.

Invesco Exchange-Traded Fund Trust II - Invesco Solar ETF

Invesco Solar ETF

Invesco Solar ETF is navigating heightened market volatility as investors weigh the impact of shifting political landscapes and policy rhetoric on long-term renewable energy demand. The community is actively debating the sector's resilience, with many pointing to the structural necessity of solar to support the power-intensive growth of AI and data center infrastructure despite short-term regulatory headwinds.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending following an Endpoints News report alleging that FDA Commissioner Marty Makary attempted to force a rejection of the company's hereditary angioedema (HAE) drug application, an effort that was reportedly blocked by internal FDA scientists. Investors are actively discussing the stock's resilience, as the company maintains its path toward potential approval for the first oral on-demand treatment for HAE while bulls view the resulting price volatility as a favorable opportunity to increase positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

India Close To Dengue Vaccine: All About The Phase 3 Trials And More

DengiAll, which is Panacea Biotec's tetravalent live-attenuated vaccine, uses weakened strains of all four DENV serotypes. As a single-dose shot, it simplifies administration compared to other multi-dose vaccines.

HC grants interim relief on GST levy on corporate guarantees

The Punjab and Haryana High Court has provided interim relief to Panacea Biotec. The court has stayed any coercive action regarding Goods and Services Tax on corporate guarantees. This applies to guarantees issued before a recent amendment to the CGST Rules. The court is examining the retrospective application of GST.

Indian shares subdued on thin year-end trade

India’s equity benchmarks slipped on Friday as volumes thinned toward the year-end, with analysts saying that an advance depended on momentum from the quarterly earnings season starting next month. The Nifty 50 index fell 0.25% to 26,077.85, while the BSE Sensex index shed 0.26% to 85,186.61, as of 9:54 a.m. IST. Most Asian markets, including India, were closed on Thursday for the Christmas holiday. Twelve of the 16 major sectors logged losses. Both the Nifty and Sensex hit record highs in November after 14 months, but have remained subdued so far in December, shedding about 0.3% and 0.5%, respectively. “We expect Indian equities to trade in a narrow range in the remaining sessions of 2025 due to a lack of triggers and reduced trading activity due to holidays across several global markets,” said Siddhartha Khemka, head of research of wealth management at Motilal Oswal Financial Services. Financial institutions such as banks and investment firms likely indulged in year-end book squaring, a process to close out or rebalance their positions to tidy up books.

Panacea Biotec bags Rs 127 crore order for oral polio vaccines

Panacea Biotec has secured a significant deal to supply bivalent oral polio vaccines valued at Rs 127.2 crore to the Central Medical Services Society. This crucial supply, confirmed via a Letter of Acceptance, will be delivered in multiple phases over 90 to 480 days, bolstering India's ongoing polio eradication efforts.

Hyderabad’s AIIMS Bibinagar leads final trials for India’s first indigenous dengue vaccine

Hyderabad’s AIIMS Bibinagar has emerged as a crucial site for India’s first indigenous dengue vaccine, currently in phase III clinical trials. Led by ICMR and developed in partnership with Panacea Biotec, the single-shot tetravalent vaccine is in its final phase of enrollment.

Panacea Biotec Ltd. is a biotechnology company, which engages in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. It operates through the Vaccines and Formulations segments. Its products cover a range of medical areas such as renal disease management, nephrology, oncology, diabetes management, and pediatric vaccines. The company was founded by Soshil Kumar Jain on February 2, 1984 and is headquartered in New Delhi, India.

Current Price	321.95
Prev Close	328.00
Open	327.00
Dividend Yield	0.00%
50-Day Moving Average	345.07
Beta	-0.15
Avg. Volume	142,885.05
PE Ratio	-254.61

52-Week High	581.90
52-Week Low	292.40
Market Capitalization	19.78B
EPS (Annual)	-1.37
Price to Book	2.40
Revenue Per Employee	3.83M

PANACEABIO.NSE
Panacea Biotec Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest PANACEABIO.NSE News

PANACEABIO.NSEPanacea Biotec Ltd.